Cross-talk between MAP kinase pathways is involved in IGF-independent, IGFBP-6-induced Rh30 rhabdomyosarcoma cell migration

Journal of Cellular Physiology

Volumn 224, Issue 3, 2010, Pages 636-643

  Fu, Ping ^a   Liang, Guang Jun ^a   Khot, Sahil S ^a   Phan, Robert ^a   Bach, Leon A ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b The Alfred ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 6; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CHEMOTAXIS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; WILD TYPE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 6; INSULIN-LIKE GROWTH FACTOR II; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RHABDOMYOSARCOMA;

EID: 77954586730     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22156     Document Type: Article

References (42)

1. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. 1995. PD 098059 is a specific inhibitor of the activation ofmitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270:27489-27494.
2. Bach LA. 2005. IGFBP-6 five years on; not so 'forgotten'? Growth Horm IGF Res 15:185-192.
3. Bach LA, Headey SJ, Norton RS. 2005. IGF-binding proteins - The pieces are falling into place. Trends Endocrinol Metab 16:228-234.
4. Bain J, McLauchlan H, Elliott M, Cohen P. 2003. The specificities of protein kinase inhibitors: An update. Biochem J 371:199-204. (Pubitemid 36458094)
5. Brown MD, Sacks DB. 2009. Protein scaffolds in MAP kinase signalling. Cell Signal 21:462-469.
6. Cuevas BD, Abell AN, Witowsky JA, Yujiri T, Johnson NL, Kesavan K, Ware M, Jones PL, Weed SA, DeBiasi RL, Oka Y, Tyler KL, Johnson GL. 2003. MEKK1 regulates calpain-dependent proteolysis of focal adhesion proteins for rear-end detachment of migrating fibroblasts. EMBO J 22:3346-3355.
7. Davies SP, Reddy H, Caivano M, Cohen P. 2000. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105.
8. Dhillon AS, Hagan S, Rath O, Kolch W. 2007. MAP kinase signalling pathways in cancer. Oncogene 26:3279-3290. (Pubitemid 46763021)
9. Ebisuya M, Kondoh K, Nishida E. 2005. The duration, magnitude and compartmentalization of ERK MAP kinase activity: Mechanisms for providing signaling specificity. J Cell Sci 118:2997-3002. (Pubitemid 41149904)
10. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, Church D, Hassan AB. 2005. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 205:145-153. (Pubitemid 40227987)
11. Fu P, Thompson JA, Bach LA. 2007a. Promotion of cancer cell migration: An insulin-like growth factor (IGF)-independent action of IGF-binding protein-6. J Biol Chem 282:22298-22306. (Pubitemid 47267353)
12. Fu P, Thompson JA, Leeding KS, Bach LA. 2007b. Insulin-like growth factors induce apoptosis as well as proliferation in LIM 1215 colon cancer cells. J Cell Biochem 100:58-68. (Pubitemid 44958179)
13. Gallicchio MA, Kneen M, Hall C, Scott AM, Bach LA. 2001. Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo. Int J Cancer 94:645-651. (Pubitemid 33035683)
14. Gallicchio MA, Kaun C, Wojta J, Binder B, Bach LA. 2003. Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro. J Cell Physiol 197:131-138. (Pubitemid 37486235)
15. Glading A, Uberall F, Keyse SM, Lauffenburger DA, Wells A. 2001. Membrane proximal ERK signaling is required for M-calpain activation downstream of epidermal growth factor receptor signaling. J Biol Chem 276:23341-23348. (Pubitemid 37410717)
16. Grellier P, De Galle B, Babajko S. 1998. Expression of insulin-like growth factor-binding protein 6 complementary DNA alters neuroblastoma cell growth. Cancer Res 58:1670-1676. (Pubitemid 28215091)
17. Hochman E, Castiel A, Jacob-Hirsch J, Amariglio N, Izraeli S. 2006. Molecular pathways regulating pro-migratory effects of Hedgehog signaling. J Biol Chem 281:33860-33870. (Pubitemid 46036598)
18. Huang C, Rajfur Z, Borchers C, Schaller MD, Jacobson K. 2003. JNK phosphorylates paxillin and regulates cell migration. Nature 424:219-223. (Pubitemid 36858692)
19. Huang C, Jacobson K, Schaller MD. 2004. MAP kinases and cell migration. J Cell Sci 117:4619-4628.
20. Ishibe S, Joly D, Zhu X, Cantley LG. 2003. Phosphorylation-dependent paxillin-ERK association mediates hepatocyte growth factor-stimulated epithelial morphogenesis. Mol Cell 12:1275-1285. (Pubitemid 37487934)
21. Kawauchi T, Chihama K, Nabeshima Y, Hoshino M. 2003. The in vivo roles of STEF/Tiam1, Rac1 and JNK in cortical neuronal migration. EMBO J 22:4190-4201. (Pubitemid 37021747)
22. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. 1997. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 137:481-492. (Pubitemid 27181299)
23. Kokkinakis DM, Rushing EJ, Shareef MM, Ahmed MM, Yang S, Singha UK, Luo J. 2004. Physiology and gene expression characteristics of carcinogen-initiated and tumor-transformed glial progenitor cells derived from the CNS of methylnitrosourea (MNU)-treated Sprague-Dawley rats. J Neuropathol Exp Neurol 63:1182-1199.
24. Kolsch V, Charest PG, Firtel RA. 2008. The regulation of cell motility and chemotaxis by phospholipid signaling. J Cell Sci 121:551-559. (Pubitemid 351524153)
25. Leng SL, Leeding KS, Gibson PR, Bach LA. 2001. Insulin-like growth factor-II renders LIM 2405 human colon cancer cells resistant to butyrate-induced apoptosis: A potential mechanism for colon cancer cell survival in vivo. Carcinogenesis 22:1625-1631.
26. Mazumdar A, Adam L, Boyd D, Kumar R. 2001. Heregulin regulation of urokinase plasminogen activator and its receptor: Human breast epithelial cell invasion. Cancer Res 61:400-405. (Pubitemid 32095743)
27. McKay MM, Morrison DK. 2007. Integrating signals from RTKs to ERK/MAPK. Oncogene 26:3113-3121.
28. Nordqvist AC, Mathiesen T. 2002. Expression of IGF-II, IGFBP-2, -5, and -6 in meningiomas with different brain invasiveness. J Neurooncol 57:19-26. (Pubitemid 34692610)
29. Pozo J, Martos-Moreno GA, Barrios V, Argente J. 2005. The IGF system in childhood: Physiology and clinical implications. J Endocrinol Invest 28:38-42.
30. Rincon M, Davis RJ. 2009. Regulation of the immune response by stress-activated protein kinases. Immunol Rev 228:212-224.
31. Smirnova T, Segall JE. 2007. Amoeboid chemotaxis: Future challenges and opportunities. Cell Adh Migr 1:165-170.
32. Soon LL. 2007. A discourse on cancer cell chemotaxis: Where to from here? IUBMB Life 59:60-67.
33. Stephens L, Milne L, Hawkins P. 2008. Moving towards a better understanding of chemotaxis. Curr Biol 18:R485-494. (Pubitemid 351734644)
34. Sueoka N, Lee HY, Wiehle S, Cristiano RJ, Fang B, Ji L, Roth JA, Hong WK, Cohen P, Kurie JM. 2000. Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene 19:4432-4436.
35. Ventura JJ, Hubner A, Zhang C, Flavell RA, Shokat KM, Davis RJ. 2006. Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell 21:701-710. (Pubitemid 43290736)
36. Wada T, Stepniak E, Hui L, Leibbrandt A, Katada T, Nishina H, Wagner EF, Penninger JM. 2008. Antagonistic control of cell fates by JNK and p38-MAPK signaling. Cell Death Differ 15:89-93. (Pubitemid 350286176)
37. Wagner EF, Nebreda AR. 2009. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9:537-549.
38. Wu WS, Wu JR, Hu CT. 2008. Signal cross talks for sustained MAPK activation and cell migration: The potential role of reactive oxygen species. Cancer Metastasis Rev 27:303-314.
39. Yamada KM, Even-Ram S. 2002. Integrin regulation of growth factor receptors. Nat Cell Biol 4:E75-76. (Pubitemid 34308845)
40. Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P, Yu D. 2001. Multiple signaling pathways involved in activation ofmatrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 20:8066-8074. (Pubitemid 34028331)
41. York RD, Yao H, Dillon T, Ellig CL, Eckert SP, McCleskey EW, Stork PJ. 1998. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature 392:622-626. (Pubitemid 28207722)
42. Zhang H, Shi X, Hampong M, Blanis L, Pelech S. 2001. Stress-induced inhibition of ERK1 and ERK2 by direct interaction with p38 MAP kinase. J Biol Chem 276:6905-6908. (Pubitemid 37391982)